Cerus Corporation 2021 Form 10-K Summary
Business context and reporting period
Cerus Corporation filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2021. The company develops and commercializes the INTERCEPT Blood System, designed to reduce pathogens in transfusion products. Commercial products include systems for platelets and plasma, the FDA-approved cryoprecipitation system, and INTERCEPT Fibrinogen Complex (IFC). The red blood cell system remains in development.
Cerus operates in one blood-safety segment. Product revenue is generated primarily in the United States, Europe, the Middle East and Africa, and other international markets. The company had 294 employees at December 31, 2021, and its common stock trades on Nasdaq under the symbol CERS.
Financial performance and key metrics
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| Product revenue | $130.9 million | $91.9 million | 42% increase |
| Government contract revenue | $28.7 million | $22.3 million | 28% increase |
| Total revenue | $159.5 million | $114.2 million | 40% increase |
| Gross profit on product revenue | $67.4 million | $50.8 million | 33% increase |
| Product gross margin | 51% | 55% | Down 4 percentage points |
| Research and development expense | $63.7 million | $64.4 million | 1% decrease |
| Selling, general and administrative expense | $81.3 million | $67.0 million | 21% increase |
| Loss from operations | $(48.9) million | $(58.3) million | Improved by $9.4 million |
| Net loss attributable to Cerus | $(54.4) million | $(59.9) million | Improved by $5.5 million |
| Basic and diluted loss per share | $(0.32) | $(0.37) | Improved |
| Net cash used in operating activities | $(33.9) million | $(41.8) million | Improved by $7.9 million |
Product revenue growth was driven primarily by higher U.S. platelet-kit sales and, to a lesser extent, favorable Euro exchange rates. U.S. product revenue increased to $67.5 million from $31.5 million, while France generated $20.9 million. The American Red Cross represented 30% of product revenue and Établissement Français du Sang represented 16%, highlighting customer concentration.
The decline in product gross margin reflected an unfavorable mix toward U.S. platelet kits used for a single therapeutic dose. Operating expenses exceeded gross profit and government contract revenue, so Cerus continued to report substantial losses. Stock-based compensation increased to $23.6 million from $18.0 million.
Liquidity, cash flow and debt
| Balance-sheet item | December 31, 2021 | December 31, 2020 |
|---|---|---|
| Cash and cash equivalents | $48.8 million | $36.6 million |
| Short-term investments | $80.6 million | $97.0 million |
| Restricted cash | $2.3 million | $2.3 million |
| Total debt | $69.4 million | $48.1 million |
| Working capital | $108.5 million | $123.5 million |
Cash, cash equivalents, short-term investments and restricted cash totaled $131.6 million at year-end. Operating cash use declined, but inventory investment increased substantially; total inventory was $42.8 million, including $16.0 million classified as non-current. Investing activities provided $12.7 million, principally from investment maturities and sales, while financing activities provided $34.3 million.
Total debt consisted of a $55.0 million term loan and $14.7 million drawn under a revolving credit facility. The term loan matures in March 2024, requires interest-only payments through March 2023, and is secured by substantially all company assets subject to exclusions. The company was in compliance with its debt covenants at year-end. Principal repayments of $41.3 million are scheduled for 2023 and $13.8 million for 2024.
Management stated that available liquidity, product sales and expected government-contract receipts should fund requirements for at least the next 12 months, but cautioned that this conclusion depends on assumptions regarding revenue, BARDA funding, expenses and capital-market access.
Material changes versus the prior comparable period
- Total revenue increased 40%, led by a 42% increase in product revenue and a 28% increase in government-contract revenue.
- Operating loss and net loss narrowed, but Cerus remained unprofitable.
- Product gross margin declined from 55% to 51% due primarily to product mix.
- SG&A increased 21%, mainly from higher stock-based and incentive compensation and investments supporting IFC commercialization.
- Operating cash use improved by $7.9 million, although inventory-related cash use increased to $19.6 million from $4.0 million.
- Debt increased by $21.3 million, including a $15.0 million term-loan draw and higher revolver borrowings.
- U.S. product revenue more than doubled, while international product revenue remained relatively stable in aggregate.
- Cerus began supplying cryoprecipitation kits to selected blood centers and completed its first IFC sale to a hospital customer.
- The company resubmitted its European red blood cell CE Mark application under the new MDR in June 2021 and does not expect an approval decision for at least another 12 months, if ever.
- BARDA committed funding of up to $126.5 million as of year-end, with total potential funding of up to $223.5 million through December 2023, subject to future option exercises and milestones.
Guidance, outlook, commentary and risks
Management expects product revenue to increase with continued U.S. expansion, broader INTERCEPT adoption, and IFC commercialization. It expects additional research and development and SG&A spending, including for red blood cell clinical trials, post-approval studies, product configurations, next-generation illuminators and regulatory activities. The filing does not provide a specific numerical revenue, profitability or cash-flow forecast.
- COVID-19: The pandemic delayed RedeS and ReCePI enrollment, restricted customer access, disrupted hospital activities and could continue to affect suppliers, sales, clinical trials and government-contract milestones.
- Red blood cell development: U.S. Phase 3 studies remain subject to recruitment delays, additional clinical and in-vitro requirements, potential antibody events and possible clinical holds. Two S-303 antibody events without hemolysis were detected in RedeS and three similar events in ReCePI; their clinical significance was not established in the filing.
- Regulatory risk: Existing European platelet and plasma approvals must transition to MDR requirements. The red blood cell system has not received marketing approval anywhere.
- Manufacturing concentration: Cerus relies on third parties, including Fresenius as the sole supplier of certain disposable kits. Nova’s illuminator agreement expires in September 2022, and the current illuminator is being phased out while a redesign is developed and requires regulatory approval.
- Commercial adoption: The U.S. blood-collection market is highly concentrated, and adoption depends on blood-center validation, hospital implementation, reimbursement and compliance with FDA bacterial-risk guidance.
- BARDA dependence: Future funding is discretionary, subject to milestones, audits and government termination rights. Unexercised potential funding is not assured.
- IFC commercialization: Broader U.S. sales depend on blood-center process validations and site-specific FDA licenses. Cerus has limited experience selling finished biologics directly to hospitals.
- Profitability and capital: Cerus expects continued losses and may require additional debt or equity financing. Equity issuance could dilute existing shareholders.
- Other risks: Customer concentration, foreign-exchange exposure, inflation, supply-chain constraints, debt covenants, intellectual-property challenges, product liability, data-security incidents and earthquake-related business interruption are material considerations.
Most important facts for investors to verify
- Whether U.S. platelet and plasma adoption continues to support the reported growth in product revenue, particularly among the American Red Cross and other concentrated customers.
- The timing, scope and economics of IFC commercialization, including additional blood-center licenses, hospital demand and potential consignment-related costs.
- Progress, antibody-event implications, enrollment and regulatory requirements for the RedeS and ReCePI red blood cell studies.
- Whether the red blood cell system receives CE Mark or FDA approval and whether additional clinical or safety data are required.
- Availability and regulatory approval of the redesigned illuminator before existing inventory and supply arrangements become constrained.
- Continuation and exercise of BARDA funding options, reimbursement audits and the effect of any delays or termination.
- Liquidity runway after considering operating cash burn, inventory commitments, debt repayments, interest expense and potential financing needs.
- Compliance with debt covenants and the ability to meet the scheduled $55.0 million term-loan principal repayments in 2023 and 2024.
- Execution against the company’s $30.4 million of disclosed short- and long-term purchase commitments and its reliance on sole or limited suppliers.
- The effect of customer concentration, foreign-exchange movements and the decline in product gross margin on future profitability.